Section Arrow
CRBU.NASDAQ
- Caribou Biosciences
Quotes are at least 15-min delayed:2026/06/26 08:04 EDT
Pre Market
Last
 1.5987
+0.0287 (+1.83%)
Bid
1.58
Ask
1.6
High 1.6072 
Low 1.55 
Volume 2.70K 
Regular Hours (Closed)
Last
 1.57
-0.09 (-5.42%)
Day High 
1.6899 
Prev. Close
1.66 
1-M High
2.49 
Volume 
1.64M 
Bid
1.58
Ask
1.6
Day Low
1.56 
Open
1.68 
1-M Low
1.57 
Market Cap 
164.64M 
Currency 美元 
P/E -- 
%Yield -- 
10-SMA 1.66 
20-SMA 1.9 
50-SMA
52-W High 3.535 
52-W Low 1.22 
Exchange NASDAQ 
Valuation Estimation
EPS (Current/Estimated)
-1.42/-1.38
Enterprise Value
190.67M
Balance Sheet
Book Value Per Share
1.03
Cash Flow
Cash Flow Yield
--
Income Statement
Total Revenue
11.16M
Operating Revenue Per Share
0.35
Industry Comparison
Code Name   Last Change Change (%) P/E P/E Range
TECHBio-Techne Corp70.7+11.825+20.08%84.11PE
Pre Market 71.075 +0.375 +0.53%
HUMAHumacyte0.62-0.0777-11.14%-- 
Pre Market 0.63 +0.01 +1.61%
NUVBNuvation Bio5.81-0.65-10.06%-- 
Pre Market 5.6479 -0.1621 -2.79%
RXRXRecursion Pharmaceuticals3.34+0.11+3.41%-- 
Pre Market 3.32 -0.02 -0.60%
SLSSELLAS Life Sciences Group10.53+1.36+14.83%-- 
Pre Market 10.4715 -0.0585 -0.56%
Industry overview quotes are at least 15 minutes delayed (Except Overnight Trading Session)
Business Description
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. The company is focused on advancing two clinical-stage allogeneic CAR-T cell therapy product candidates for the treatment of patients with hematologic malignancies: Vispacabtagene regedleucel and CB-011. It operates in one reportable segment, which is the business of developing allogeneic CAR-T cell therapies. Geographically, it operates in the United States and the rest of the World, of which the United States derives the maximum revenue.
Information provided by: etnet
Terms and Conditions
Bank of China (Hong Kong) Limited
Disclaimer:
This information is provided by ET Net Limited ("ET Net") and/or its third party information providers (the "Sources") and is strictly for reference only. It is not intended to provide any financial or professional advice and any person should not rely upon the same as such. You should obtain relevant and specific professional advice before making any investment decision. Before making an investment decision, you should consider, with the assistance of your professional securities adviser, whether the information is appropriate in light of your particular investment needs, objectives and financial circumstances. ET Net and the Sources endeavor to ensure the accuracy and reliability of the information provided. Notwithstanding the aforesaid, ET Net, the Sources and Bank of China (Hong Kong) Limited do not guarantee or make any representation, warranty or undertaking as to the accuracy, reliability, completeness or timeliness of this information, and accept no responsibility or liability whatsoever (whether in tort or contract or otherwise) for any loss or damage howsoever arising from or in reliance upon the whole or any part of such information.